8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
‎Washington, D.C. 20549
‎___________________________________________

FORM 8-K

___________________________________________

CURRENT REPORT
‎PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934
‎

Date of Report (Date of earliest event reported): February 17, 2022
‎___________________________________________

ARTIVION, INC.

(Exact name of registrant as specified in its charter)
‎___________________________________________

Delaware	1-13165	59-2417093
(State or Other Jurisdiction ‎of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

1655 Roberts Boulevard, N.W., Kennesaw, Georgia 30144
‎(Address of principal executive office) (zip code)
‎

Registrant's telephone number, including area code: (770) 419-3355
‎

_________________________________________________________

(Former name or former address, if changed since last report)

Title of each class	Trading Symbol(s)	Name of each exchange ‎on which registered
Common Stock, $0.01 par value	AORT	NYSE

___________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

‎

Item 2.02Results of Operations and Financial Condition

On February 17, 2022, Artivion, Inc. (“Artivion” or the “Company”) issued a press release announcing its financial results for the quarter ended December 31, 2021. Artivion hereby incorporates by reference herein the information set forth in its press release dated February 17, 2022, a copy of which is attached hereto as Exhibit 99.1. Except as otherwise provided in the press release, the press release speaks only as of the date of such press release and it shall not create any implication that the affairs of Artivion have continued unchanged since such date.

The information provided pursuant to this Item 2.02 is to be considered “furnished” pursuant to Item 2.02 of Form 8-K and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended, nor shall it be deemed incorporated by reference into any of Artivion’s reports or filings with the Securities and Exchange Commission, whether made before or after the date hereof, except as expressly set forth by specific reference in such report or filing.

Except for the historical information contained in this report, the statements made by Artivion are forward-looking statements that involve risks and uncertainties. All such statements are subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Artivion’s future financial performance could differ significantly from the expectations of management and from results expressed or implied in the press release. Please refer to the last paragraph of the text portion of the press release for further discussion about forward-looking statements. For further information on risk factors, please refer to “Risk Factors” contained in Artivion’s most recently filed Form 10-K and its subsequent filings with the Securities and Exchange Commission, as well as in the press release attached as Exhibit 99.1 hereto. Artivion disclaims any obligation or duty to update or modify these forward-looking statements.

Item 9.01(d) Exhibits

(d) Exhibits.

Exhibit Number	Description
99.1*	Press Release dated February 17, 2022
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

* Furnished herewith, not filed.

‎

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, Artivion, Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 17, 2022

ARTIVION, INC.
By:	/s/ D. Ashley Lee
Name:	D. Ashley Lee
Title:	Executive Vice President, Chief Operating Officer and Chief Financial Officer

-3-

EX-99.1

Exhibit 99.1

FOR IMMEDIATE RELEASE

Contacts:

Artivion D. Ashley Lee Executive Vice President, Chief Financial Officer and Chief Operating Officer Phone: 770-419-3355 Gilmartin Group LLC Brian Johnston / Lynn Lewis Phone:  332-895-3222 investors@artivion.com

Artivion Reports Fourth Quarterand Full Year 2021 Financial Results

Fourth Quarter and Recent Business Highlights:

· Achieved record revenue of $79.4 million in the fourth quarter 2021 versus $67.9 million in the fourth quarter of 2020, an increase of 16.9% on a GAAP basis and 18.8 % on a non-GAAP proforma constant currency basis

· Received FDA approval to launch enrollment in AMDS clinical trial

· Filed PMA with FDA for US PerClot Approval in October 2021

ATLANTA, GA – (February 17, 2022) – Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced its financial results for the fourth quarter and full year ended December 31, 2021.

“In the fourth quarter we achieved record quarterly revenues, driven by our aortic stent grafts and continued strength in our US On-X aortic valve business. We also saw meaningful growth across APAC and LATAM as we continue to expand our commercial footprint and secure additional regulatory approvals in those regions,” said Pat Mackin, Chairman, President, and Chief Executive Officer.

“In addition to our commercial and regulatory success, we also continued to advance our product pipeline, which is expected to drive growth in both the near and longer terms. We believe we are on track to receive FDA PMA approval for PROACT Mitral and for PerClot this year. Meanwhile, we have made significant progress with enrollment in our PROACT Xa trial and have advanced several other programs that are expected to deliver incremental growth beginning in 2025.”

“Despite the unprecedented challenges due to the COVID-19 pandemic, we were able to execute on our key initiatives. We expect that momentum to continue as reflected in our positive financial outlook. The rollout of our new corporate branding is timely as we are now firmly established in the marketplace as an innovator and leader in the treatment of aortic repair.”

Page 1 of 9

Fourth Quarter 2021 Financial Results

Total revenues for the fourth quarter of 2021 were $79.4 million, reflecting an increase of 16.9% on a GAAP basis and 18.8% on a non-GAAP proforma constant currency basis, both compared to the fourth quarter of 2020.

Net loss for the fourth quarter of 2021 was ($20.1) million, or ($0.51) per fully diluted common share, compared to net loss of ($3.5) million, or ($0.09) per fully diluted common share for the fourth quarter of 2020. Non-GAAP net loss for the fourth quarter of 2021 was ($141,000), or ($0.00) per fully diluted common share, compared to non-GAAP net income of $7.9 million, or $0.20 per fully diluted common share for the fourth quarter of 2020. GAAP net loss for the fourth quarter of 2021 includes pretax expense of $10.4 million for business development expenses primarily related to non-cash charges from the Ascyrus and Endospan transactions and $2.4 million of losses due to foreign currency.

Full Year 2021 Financial Results

Total revenues for 2021 were $298.8 million, reflecting an increase of 18.0% on a GAAP basis and 15.8% on a non-GAAP proforma constant currency basis compared to the full year of 2020.

Net loss for 2021 was ($14.8) million, or ($0.38) per fully diluted common share, compared to net loss of ($16.7) million, or ($0.44) per fully diluted common share for the full year of 2020. Non-GAAP net income for the full year of 2021 was $4.9 million, or $0.12 per fully diluted common share, compared to non-GAAP net income of $9.7 million, or $0.25 per fully diluted common share for the full year of 2020. GAAP net loss for the full year of 2021 includes pretax expense of $16.6 million for business development expenses primarily related to non-cash charges from the Ascyrus and Endospan transactions and $5.5 million of losses due to foreign currency, partially offset by a pretax gain of $15.9 million resulting from the sale of our PerClot product line.

The independent registered public accounting firm's audit report with respect to the Company's fiscal year-end financial statements will not be issued until the Company completes its annual report on Form 10-K. Accordingly, the financial results reported in this earnings release are preliminary pending completion of the audit and the Company’s filing of its annual report on Form 10-K.

2022 Financial Outlook

Artivion expects constant currency revenue growth of between 9.0% and 11.0% for the full year 2022 compared to the full year 2021. Assuming a Euro/USD exchange rate of 1.13and the related 2%, or approximately $6.0 million revenue headwind compared to 2021, revenues are expected to be in the range of $319.0 million to $325.0 million.

The Company's financial performance for 2022 and future periods is subject to the risks identified below.

Non-GAAP Financial Measures

This press release contains non-GAAP financial measures, including non-GAAP revenue, non-GAAP net income, non-GAAP EBITDA, non-GAAP general, administrative, and marketing, and non-GAAP adjusted operating income. Investors should consider this non-GAAP information in addition to, and not as a substitute for, financial measures prepared in accordance with US GAAP. In addition, this non-GAAP financial information may not be the same as similar measures presented by other companies. The Company's non-GAAP revenues are adjusted for revenues of acquired and divested product lines and the impact of changes in currency exchange. The Company’s non-GAAP net income; non-GAAP EBITDA;  non-GAAP general, administrative, and marketing;  and non-GAAP adjusted operating income results exclude (as applicable) business development, integration, and severance expense; gain from sale of non-financial assets; depreciation and amortization expense; interest income and expense; non-cash interest expense; loss (gain) on foreign

Page2 of 12

currency revaluation; stock-based compensation expense; corporate rebranding expense; and income tax expense (benefit). The Company generally uses non-GAAP financial measures to facilitate management's review of the operational performance of the company and as a basis for strategic planning. Company management believes that these non-GAAP presentations provide useful information to investors regarding unusual non-operating transactions; the operating expense structure of the Company's existing and recently acquired operations, without regard to its on-going efforts to acquire additional complementary products and businesses and the transaction and integration expenses incurred in connection with recently acquired and divested product lines; and the operating expense structure excluding fluctuations resulting from foreign currency revaluation and stock-based compensation expense. The Company believes it is useful to exclude certain expenses because such amounts in any specific period may not directly correlate to the underlying performance of its business operations or can vary significantly between periods as a result of factors such as acquisitions, or non-cash expense related to amortization of previously acquired tangible and intangible assets and any related adjustments to their carrying values. The Company has adjusted for the impact of acquired and divested product lines and changes in currency exchange from certain revenues to evaluate comparable product growth rates on a constant currency basis. The Company does, however, expect to incur similar types of expenses and currency exchange impacts in the future, and this non-GAAP financial information should not be viewed as a statement or indication that these types of expenses will not recur. Company management encourages investors to review the Company's consolidated financial statements and publicly filed reports in their entirety, including the reconciliation of non-GAAP to GAAP financial measures.

Webcast and Conference Call Information

The Company will hold a teleconference call and live webcast later today, February 17, 2022 at 4:30 p.m. ET to discuss the results, followed by a question and answer session. To participate in the conference call dial 201-689-8261 a few minutes prior to 4:30 p.m. ET. The teleconference replay will be available approximately one hour following the completion of the event and can be accessed by calling (toll free) 877-660-6853 or 201-612-7415. The conference number for the replay is 13725524.

The live webcast and replay can be accessed by going to the Investors section of the Artivion website at www.Artivion.com and selecting the heading Webcasts & Presentations.

About Artivion, Inc.

Headquartered in suburban Atlanta, Georgia, Artivion, Inc. is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons’ most difficult challenges in treating patients with aortic diseases. Artivion’s four major groups of products include: aortic stents and stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues. Artivion markets and sells products in more than 100 countries worldwide. For additional information about Artivion, visit our website, www.artivion.com.  

Forward Looking Statements

Statements made in this press release that look forward in time or that express management's beliefs, expectations, or hopes are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect the views of management at the time such statements are made. These statements include our beliefs that we expect our product pipeline to drive growth in both the near and longer terms; we are on track to receive FDA PMA approval for PROACT Mitral and for PerClot this year; we havemade significant progress with enrollment in our PROACT Xa trial and have advanced several other programs that are expected to deliver incremental growth beginning in 2025; we expect our momentum gained as a result of executing on our key initiatives to continue as reflected in our positive financial outlook; and that we believe the rollout of our new corporate branding firmly establishes us in the marketplace as an innovator and leader in the treatment of aortic repair. These forward-looking statements are subject to a number of risks, uncertainties, estimates, and assumptions that may cause actual results to differ

Page3 of 12

materially from current expectations, including that the benefits anticipated from the Ascyrus Medical LLC transaction and Endospan agreements may not be achieved; the benefits anticipated from our clinical trials may not be achieved or achieved on our anticipated timeline; our existing products may not be able to consistently retain their existing regulatory approvals; products in our pipeline may not receive regulatory approval or receive regulatory approval on our anticipated timelines; our products that obtain regulatory approval may not be adopted by the market as much as we anticipate or at all;  and the continued effects of COVID-19, including new COVID-19 variants, hospital staffing shortages, decelerating vaccination or vaccine adoption rates, or government mandates implemented to address the effects of the pandemic, could adversely impact our results.  These risks and uncertainties include the risk factors detailed in our Securities and Exchange Commission filings, including our Form 10-K for year ended December 31, 2021. Artivion does not undertake to update its forward-looking statements, whether as a result of new information, future events, or otherwise.

Page4 of 12

Artivion, Inc. and Subsidiaries

Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except per share data)

	(Unaudited)
	Three Months Ended				Twelve Months Ended
	December 31,				December 31,
		2021		2020		2021		2020
Revenues:
Products	$	59,069	$	50,502	$	221,597	$	179,299
Preservation services		20,325		17,394		77,239		73,928
Total revenues		79,394		67,896		298,836		253,227
Cost of products and preservation services:
Products		18,604		14,050		65,196		50,128
Preservation services		9,416		9,255		36,126		35,315
Total cost of products and preservation services		28,020		23,305		101,322		85,443
Gross margin		51,374		44,591		197,514		167,784
Operating expenses:
General, administrative, and marketing		51,253		36,103		169,774		141,136
Research and development		9,460		6,574		35,546		24,207
Total operating expenses		60,713		42,677		205,320		165,343
Gain from sale of non-financial assets		--		--		(15,923)		--
Operating (loss) income		(9,339)		1,914		8,117		2,441
Interest expense		3,892		4,718		16,887		16,698
Interest income		(19)		(36)		(79)		(217)
Other expense (income), net		2,875		(2,676)		6,136		3,134
Loss before income taxes		(16,087)		(92)		(14,827)		(17,174)
Income tax expense (benefit)		4,013		3,366		7		(492)
Net loss	$	(20,100)	$	(3,458)	$	(14,834)	$	(16,682)
Loss per common share:
Basic	$	(0.51)		(0.09)	$	(0.38)	$	(0.44)
Diluted	$	(0.51)		(0.09)	$	(0.38)	$	(0.44)
Weighted-average common shares outstanding:
Basic		39,161		38,613		38,983		37,861
Diluted		39,161		38,613		38,983		37,861

Page5 of 12

Artivion, Inc. and Subsidiaries

Consolidated Balance Sheets

(In thousands)

	December 31,
	2021		2020
ASSETS
Current assets:
Cash and cash equivalents	$	55,010	$	61,412
Restricted securities		--		546
Trade receivables, net		53,019		45,964
Other receivables		5,086		2,788
Inventories, net		76,971		73,038
Deferred preservation costs, net		42,863		36,546
Prepaid expenses and other		14,748		14,295
Total current assets		247,697		234,589
Goodwill		250,000		260,061
Acquired technology, net		166,994		186,091
Operating lease right-of-use assets, net		45,714		18,571
Property and equipment, net		37,521		33,077
Other intangibles, net		34,502		40,966
Deferred income taxes		2,357		1,446
Other long-term assets		8,267		14,603
Total assets	$	793,052	$	789,404

Page6 of 12

Artivion, Inc. and Subsidiaries

Consolidated Balance Sheets

(In thousands)

	December 31,
	2021		2020
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	10,395	$	9,623
Accrued expenses		7,687		7,472
Accrued compensation		13,163		10,192
Taxes payable		3,634		2,808
Accrued procurement fees		3,689		3,619
Current portion of finance lease obligation		528		614
Current maturities of operating leases		3,149		5,763
Current portion of long-term debt		1,630		1,195
Current portion of contingent consideration		--		16,430
Other		1,078		2,752
Total current liabilities		44,953		60,468
Long-term debt		307,493		290,468
Contingent consideration		49,400		43,500
Non-current maturities of operating leases		44,869		14,034
Non-current finance lease obligations		4,374		5,300
Deferred income taxes		28,799		34,713
Deferred compensation liability		5,952		5,518
Other		6,484		6,690
Total liabilities		492,324		460,691
Commitments and contingencies
Shareholders' equity:
Preferred stock $0.01 par value per share, 5,000 shares authorized, no shares issued		--		--
Common stock $0.01 par value per share, 75,000 shares authorized,
41,397 and 40,394 shares issued as of December 31, 2021 and 2020, respectively		414		404
Additional paid-in capital		322,874		316,192
Retained earnings		1,975		20,022
Accumulated other comprehensive (loss) income		(9,887)		6,743
Treasury stock at cost, 1,487 shares as of December 31, 2021 and 2020		(14,648)		(14,648)
Total shareholders' equity		300,728		328,713
Total liabilities and shareholders' equity	$	793,052	$	789,404

Page7 of 12

Artivion, Inc. and Subsidiaries

Consolidated Statement of Cash Flows

(In thousands)

	Year Ended December 31,
	2021		2020		2019
Net cash flows from operating activities:
Net (loss) income	$	(14,834)	$	(16,682)	$	1,720
Adjustments to reconcile net (loss) income to net cash from operating activities:
Depreciation and amortization		23,977		20,712		18,317
Non-cash compensation		10,711		6,912		8,799
Change in fair value of contingent consideration		8,870		4,523		--
Non-cash lease expense		7,521		7,145		5,009
Write-down of inventories and deferred preservation costs		5,377		3,443		1,488
Write-off of Endospan Option		4,944		--		--
Non-cash interest expense		2,005		3,656		1,631
Change in fair value of long-term loan receivable		409		4,949		--
Deferred income taxes		(4,470)		4,283		(2,305)
Gain on sale of non-financial assets		(15,923)		--		--
Other		2,060		124		551
Changes in operating assets and liabilities:
Prepaid expenses and other assets		(1,404)		(2,720)		(6,177)
Accounts payable, accrued expenses, and other liabilities		(1,893)		(9,157)		251
Receivables		(11,560)		9,938		(5,332)
Inventories and deferred preservation costs		(18,375)		(24,757)		(8,125)
Net cash flows (used in) provided by operating activities		(2,585)		12,369		15,827
Net cash flows from investing activities:
Proceeds from sale of non-financial assets, net		19,000		--		--
Ascyrus Acquisition, net of cash acquired		--		(59,119)		--
Payments for Endospan agreement		--		(5,000)		(15,000)
Capital expenditures		(13,091)		(7,328)		(8,072)
Other		(249)		(1,681)		(871)
Net cash flows provided by (used in) investing activities		5,660		(73,128)		(23,943)
Net cash flows from financing activities:
Proceeds from exercise of stock options and issuance of common stock		3,756		2,432		4,758
Proceeds from issuance of convertible debt		--		100,000		--
Proceeds from revolving line of credit		--		30,000		--
Proceeds from financing insurance premiums		--		2,815		--
Repayment of revolving line of credit		--		(30,000)		--
Redemption and repurchase of stock to cover tax withholdings		(1,914)		(1,995)		(2,743)
Payment of debt issuance costs		(2,219)		(3,647)		--
Repayment of debt		(3,085)		(5,346)		(2,780)
Payment of contingent consideration		(8,200)		--		--
Other		(561)		(651)		(728)
Net cash flows (used in) provided by financing activities		(12,223)		93,608		(1,493)
Effect of exchange rate changes on cash, cash equivalents, and restricted securities		2,200		(5,185)		1,667
(Decrease) increase in cash, cash equivalents, and restricted securities		(6,948)		27,664		(7,942)
Cash, cash equivalents, and restricted securities, beginning of year		61,958		34,294		42,236
Cash, cash equivalents, and restricted securities, end of year	$	55,010	$	61,958	$	34,294

Page8 of 12

Artivion, Inc. and Subsidiaries

Financial Highlights

(In thousands)

	(Unaudited)				(Unaudited)
	Three Months Ended				Twelve Months Ended
	December 31,				December 31,
	2021		2020		2021		2020
Products:
Aortic stents and stent grafts	$	23,222	$	17,731	$	85,387	$	61,663
Surgical sealants		18,478		17,083		70,714		62,068
On-X		15,520		13,668		57,363		48,053
Other		1,849		2,020		8,133		7,515
Total products		59,069		50,502		221,597		179,299
Preservation services		20,325		17,394		77,239		73,928
Total revenues	$	79,394	$	67,896	$	298,836	$	253,227
Revenues:
U.S.	$	39,622	$	35,103	$	151,151	$	138,274
International		39,772		32,793		147,685		114,953
Total revenues	$	79,394	$	67,896	$	298,836	$	253,227

Page9 of 12

Artivion, Inc. and Subsidiaries

Reconciliation of GAAP to Non-GAAP

Revenues and General Administrative, and Marketing Expense

(In thousands, except per share data)

	(Unaudited)					(Unaudited)
	Three Months Ended					Twelve Months Ended
	December 31,					December 31,
	2021		2020		Growth Rate	2021		2020		Growth Rate
Reconciliation of total revenues, GAAP to
total revenues, non-GAAP:
Total revenues, GAAP	$	79,394	$	67,896	16.9%	$	298,836	$	253,227	18.0%
Including AMDS prior to acquisition		--		--			--		2,088
Excluding PerClot post sale		--		(801)			--		(1,299)
Impact of changes in currency exchange		--		(283)			--		4,088
Total proforma constant currency revenue, non-GAAP	$	79,394	$	66,812	18.8%	$	298,836	$	258,104	15.8%

	(Unaudited)				(Unaudited)
	Three Months Ended				Twelve Months Ended
	December 31,				December 31,
	2021		2020		2021		2020
Reconciliation of G&A expenses, GAAP to
adjusted G&A, non-GAAP:
General, administrative, and marketing expense, GAAP	$	51,253	$	36,103	$	169,774	$	141,136
Operating business development, integration, and severance expense		(10,012)		(4,839)		(16,150)		(7,371)
Adjusted G&A, non-GAAP:	$	41,241	$	31,264	$	153,624	$	133,765

Page10 of 12

Artivion, Inc. and Subsidiaries

Reconciliation of GAAP to Non-GAAP

Operating Income and Adjusted EBITDA

(In thousands, except per share data)

	(Unaudited)				(Unaudited)
	Three Months Ended				Twelve Months Ended
	December 31,				December 31,
	2021		2020		2021		2020
Reconciliation of operating (loss) income, GAAP to
adjusted operating income, non-GAAP:
Operating (loss) income	$	(9,339)	$	1,914	$	8,117	$	2,441
Gain from sale of non-financial assets		--		--		(15,923)		--
Amortization expense		4,119		4,334		16,820		13,764
Operating business development, integration, and severance expense		10,012		4,839		16,150		7,371
Corporate rebranding expense		905		15		1,428		336
Adjusted operating income, non-GAAP	$	5,697	$	11,102	$	26,592	$	23,912

	(Unaudited)				(Unaudited)
	Three Months Ended				Twelve Months Ended
	December 31,				December 31,
	2021		2020		2021		2020
Reconciliation of net loss, GAAP to
adjusted EBITDA, non-GAAP:
Net loss, GAAP	$	(20,100)	$	(3,458)	$	(14,834)	$	(16,682)
Adjustments:
Depreciation and amortization expense		5,969		5,894		23,977		20,712
Interest expense		3,892		4,718		16,887		16,698
Business development, integration, and severance expense		10,421		4,839		16,559		12,320
Stock-based compensation expense		3,240		(520)		10,711		6,912
Corporate rebranding expense		905		15		1,428		336
Interest income		(19)		(36)		(79)		(217)
Income tax expense (benefit)		4,013		3,366		7		(492)
Gain from sale of non-financial assets		--		--		(15,923)		--
Loss (income) on foreign currency revaluation		2,447		(2,688)		5,545		(1,829)
Adjusted EBITDA, non-GAAP	$	10,768	$	12,130	$	44,278	$	37,758

Page11 of 12

Artivion, Inc. and Subsidiaries

Reconciliation of GAAP to Non-GAAP

Net Loss and Diluted Loss Per Common Share

(In thousands, except per share data)

	(Unaudited)				(Unaudited)
	Three Months Ended				Twelve Months Ended
	December 31,				December 31,
		2021		2020		2021		2020
GAAP:
Loss before income taxes	$	(16,087)	$	(92)	$	(14,827)	$	(17,174)
Income tax expense (benefit)		4,013		3,366		7		(492)
Net loss	$	(20,100)	$	(3,458)	$	(14,834)	$	(16,682)
Diluted loss per common share	$	(0.51)	$	(0.09)	$	(0.38)	$	(0.44)
Diluted weighted-average common
shares outstanding		39,161		38,613		38,983		37,861
Reconciliation of loss before income taxes, GAAP
to adjusted (loss) income before income taxes, non-GAAP:
Loss before income taxes, GAAP	$	(16,087)	$	(92)	$	(14,827)	$	(17,174)
Adjustments:
Business development, integration, and severance expense		10,421		4,839		16,559		12,320
Amortization expense		4,119		4,334		16,820		13,764
Gain from sale of non-financial assets		--		--		(15,923)		--
Non-cash interest expense		454		1,395		2,479		3,656
Corporate rebranding expense		905		15		1,428		336
Adjusted (loss) income before income taxes,
non-GAAP		(188)		10,491		6,536		12,902
Income tax expense calculated at a pro forma tax rate of 25%		(47)		2,623		1,634		3,226
Adjusted (loss) income, non-GAAP	$	(141)	$	7,868	$	4,902	$	9,676
Reconciliation of diluted loss per common share, GAAP
to adjusted diluted (loss) income per common share, non-GAAP:
Diluted (loss) income per common share, GAAP:	$	(0.51)	$	(0.09)	$	(0.38)	$	(0.44)
Adjustments:
Business development, integration, and severance expense		0.26		0.12		0.42		0.32
Amortization expense		0.10		0.11		0.43		0.36
Gain from sale of non-financial assets		--		--		(0.41)		--
Non-cash interest expense		0.01		0.04		0.06		0.09
Corporate rebranding expense		0.03		--		0.04		0.01
Effect of 25% pro forma tax rate		0.21		0.09		0.09		0.10
Tax effect of non-GAAP adjustments		(0.10)		(0.07)		(0.13)		(0.19)
Adjusted diluted (loss) income per common share,
non-GAAP:	$	(0.00)	$	0.20	$	0.12	$	0.25
Reconciliation of diluted weighted-average common shares outstanding
GAAP to diluted weighted-average common shares outstanding, non-GAAP:
Diluted weighted-average common shares outstanding, GAAP:		39,161		38,613		38,983		37,861
Adjustments:
Effect of dilutive stock options and awards		--		487		560		508
Effect of convertible senior notes		--		--		--		--
Diluted weighted-average common shares outstanding, non-GAAP		39,161		39,100		39,543		38,369

Page12 of 12

XML

Document And Entity Information	Feb. 17, 2022
Document And Entity Information [Abstract]
Document Type	8-K
Document Period End Date	Feb. 17, 2022
Entity Registrant Name	ARTIVION, INC.
Entity Incorporation, State or Country Code	DE
Entity File Number	1-13165
Entity Tax Identification Number	59-2417093
Entity Address, Address Line One	1655 Roberts Boulevard, N.W.
Entity Address, City or Town	Kennesaw
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	30144
City Area Code	770
Local Phone Number	419-3355
Title of 12(b) Security	Common Stock, $0.01 par value
Trading Symbol	AORT
Security Exchange Name	NYSE
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Emerging Growth Company	false
Entity Central Index Key	0000784199
Amendment Flag	false